CLR1404 clinical trials
Also written CLR 131, I-131-CLR1404 and iopofosine I 131.
How each study uses CLR1404 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CLR1404 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Cellectar Biosciences, Inc. (7) · University of Wisconsin, Madison (1) · Cellectar, Inc (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test CLR1404.
- Jun 2027Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGPhase 1 · Cellectar Biosciences, Inc.
- Jun 2027Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasPhase 1 · Cellectar Biosciences, Inc.
Studies
Open first, then newest update. How each study uses CLR1404 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsNot yet recruitingPhase 3Cellectar Biosciences, Inc.NCT07766421Written as Iopofosine I 131
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGActive, not recruitingPhase 1Cellectar Biosciences, Inc.NCT05610891Written as CLR 131
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingPhase 1Cellectar Biosciences, Inc.NCT03478462Written as CLR 131
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingPhase 2Cellectar Biosciences, Inc.NCT02952508Written as Iopofosine I 131 single dose
- CLR 131 Combined With Radiation for Head and Neck CancerCompletedPhase 1University of Wisconsin, MadisonNCT04105543Written as CLR 131
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Cellectar Biosciences, Inc.NCT02278315Written as I-131-CLR1404
- Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has ReturnedCompletedPhase 1Cellectar Biosciences, Inc.NCT01495663Written as I-131-CLR1404
- Open-Label Study of I-131-CLR1404 in Subjects With Recurrent GliomaWithdrawnPhase 2Cellectar Biosciences, Inc.NCT01778088Written as I-131-CLR1404 Injection
- Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid TumorsCompletedPhase 1Cellectar, IncNCT00925275Written as I-131-CLR1404
As the comparator · 1 — what is tested is compared with CLR1404
Codes
What other systems call CLR1404 · ClinicalTrials.gg INT000262
- MeSH (NLM) C000599353CLR1404One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599353 | CLR1404 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.